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Abstract
Background: Suicide is a leading cause of death globally. Suicide deaths are elevated in those experiencing
severe mental health problems, including schizophrenia. Psychological talking therapies are a potentially
effective means of alleviating suicidal thoughts, plans, and attempts. However, talking therapies need to i)
focus on suicidal experiences directly and explicitly, and ii) be based on testable psychological mechanisms.
The Cognitive AppRoaches to coMbatting Suicidality (CARMS) project is a Randomised Controlled Trial (RCT)
which aims to investigate both the efficacy and the underlying mechanisms of a psychological talking
therapy for people who have been recently suicidal and have non-affective psychosis.
Methods: The CARMS trial is a two-armed single-blind RCT comparing a psychological talking therapy (Cognitive
Behavioural Suicide Prevention for psychosis [CBSPp]) plus Treatment As Usual (TAU) with TAU alone. There are primary
and secondary suicidality outcome variables, plus mechanistic, clinical, and health economic outcomes measured over
time. The primary outcome is a measure of suicidal ideation at 6months after baseline. The target sample size is 250, with
approximately 125 randomised to each arm of the trial, and an assumption of up to 25% attrition. Hence, the overall
recruitment target is up to 333. An intention to treat analysis will be used with primary stratification based on National
Health Service (NHS) recruitment site and antidepressant prescription medication. Recruitment will be from NHS mental
health services in the North West of England, UK. Participants must be 18 or over; be under the care of mental health
services; have mental health problems which meet ICD-10 non-affective psychosis criteria; and have experienced self-
reported suicidal thoughts, plans, and/or attempts in the 3 months prior to recruitment. Nested qualitative work will
investigate the pathways to suicidality, experiences of the therapy, and identify potential implementation challenges
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beyond a trial setting as perceived by numerous stake-holders.
Discussion: This trial has important implications for countering suicidal experiences for people with psychosis. It will
provide definitive evidence about the efficacy of the CBSPp therapy; the psychological mechanisms which lead to suicidal
experiences; and provide an understanding of what is required to implement the intervention into services should it be
efficacious.
Trial registration: ClinicalTrials.gov (NCT03114917), 14th April 2017. ISRCTN (reference ISRCTN17776666 https://doi.org/10.
1186/ISRCTN17776666); 5th June 2017). Registration was recorded prior to participant recruitment commencing.
Keywords: Suicide, Suicidal thoughts and behaviours, Psychological interventions, Cognitive therapy, Psychosis,
Schizophrenia, Psychological suicide mechanisms, Randomised controlled trial
Background
Suicidal thoughts, plans, and fatalities are of substantial
concern worldwide. Approximately 800,000 lives are lost
to suicide, globally, every year, which equates to one per-
son dying by suicide every 40 s [1]. Estimates indicate
that approximately 48,344 people died by suicide in the
USA in 2018, which is 14.2 deaths per 100,000 popula-
tion [2]. In the UK, for 2018 registrations, there were
6507 suicide fatalities, that is, 11.2 deaths per 100,000
population [3]. Suicide deaths increased in 2018 in the
UK compared to 2013 figures [4]. In the US, the suicide
death rate has also been increasing over time [5]. Suicide
attempts are far more prevalent than suicide deaths, and
suicide thoughts are more frequent than attempts. For
example, as collected by the Adult Psychiatric Morbidity
Survey, in 2014, 21.6% of British white people in Eng-
land, UK, had suicidal thoughts whereas 6.9% had
attempted suicide [6], and 0.01% had died by suicide that
year. There were 1.4 million suicide attempts in 2017 in
the USA [2] and 47,000 suicide deaths [7].
There is sound evidence that suicidal thoughts, plans,
attempts and deaths are significantly elevated in those
with severe mental health problems [8]. For example,
mental health problems in those experiencing non-
affective psychoses, or recent onset psychosis, have been
associated with one of the highest, relatively unchanging,
suicide mortality rates across the decades [9–12]. Whilst it
is vital to focus on preventing deaths by suicide it is
equally important to focus on reducing suicidal thoughts,
plans and acts in people with severe mental health prob-
lems because they are both common and highly distres-
sing for individuals and their families. For example, up to
50% of people with non-affective psychoses will experi-
ence suicidal thoughts and/or suicide attempts [10, 13].
Furthermore, suicidal thoughts and acts are associated
with immense psychological distress [14] and can be
strong predictors of suicide fatalities [15]. For instance, as
reported by a recent meta-analysis, people with schizo-
phrenia who also had thoughts of suicide were six times
more likely to die by suicide compared to a 1.5 fold in-
crease in those experiencing depression [16]. Hence, it is
important that interventions which combat suicidal
thoughts and acts are designed to attenuate a range of
suicidal experiences, such as thoughts, urges, plans and at-
tempts, in people with severe mental health problems
such as psychosis.
A small number of meta-analytic systematic reviews
have examined the extent to which psychological and psy-
chosocial interventions reduce self-harm and suicidal ex-
periences in those with mental health problems [17–21].
For example, two reported that psychological interven-
tions were effective as long as they targeted suicidality
(i.e., suicidal thoughts, behaviours and acts) or psycho-
logical precursors of suicidal experiences (e.g., hopeless-
ness) rather than symptoms reflecting a psychiatric
diagnosis [18, 19]. One of these reviews specifically evalu-
ated the effects of cognitive-behavioural types of therapies
(CBT) on suicide thoughts and behaviours [19]. Findings
showed that cognitive behavioural therapies, including
dialectical behavioural therapy, reduced suicidal thoughts
and behaviours.
An issue with many studies included in such reviews is
that few tested the effectiveness of a psychological talk-
ing therapy which, first of all explicitly focused on sui-
cidal thoughts and acts, and second, were based on
empirically supported recent psychological models
which attempt to delineate the psychological pathways
underpinning suicidal thoughts and behaviours. The
Schematic Appraisal Model of Suicide (SAMS) [22] is
one such recent psychological model of suicide which
was developed from the influential Cry of Pain model
[23] but also resonates with other contemporary psycho-
logical models of suicide, such as the Integrated Motiv-
ational Volitional Model [24–26]. These contemporary
models converge, at least to some extent, in highlighting
the importance of perceptions of emotional dysregula-
tion, lack of social support and a perceived inability to
solve inter-personal problems together with experiences
of feeling defeated, trapped and hopelessness in path-
ways to suicidal thoughts and acts. It is important to
understand mechanisms underlying suicidal experiences
which are transdiagnostic and appear to be activated or
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triggered regardless of specific mental health problems
or psychiatric diagnoses but to also recognise that spe-
cific symptoms associated with mental health problems,
such as hallucinations, delusions, and hyperarousal may
amplify suicidal thoughts, plans and acts [27–29].
Psychological therapies are optimally efficacious and
effective if they focus on evidence-based, theoretically
derived, psychological mechanisms thought to underlie
suicidal thoughts and behaviours, and if as part of the
therapy, they address such suicidal experiences explicitly
[19]. Some of the cognitive behavioural therapies which
have been evaluated may not always have been explicitly
focused in this way. One psychological intervention ap-
proach which has focussed on ameliorating suicidal
thoughts and acts is Cognitive Behavioural Suicide Pre-
vention (CBSP) [14, 19, 30]. CBSP is based on the SAMS
[22]. It was developed by the current authors and col-
leagues [14, 30, 31] as a psychological intervention de-
signed to target suicidal thoughts, urges, plans and acts
by focusing on perceptions of poor emotional regulation,
social isolation, and difficulties with interpersonal prob-
lem solving. As these negative appraisals are posited to
give rise to perceptions of being defeated, trapped and
hopeless over time [32], and, in accord with a large body
of evidence showing that these perceptions are central in
the pathways to suicidal experiences [28, 32–42], CBSP
also targets perceptions of defeat, entrapment and hope-
lessness. Hence, CBSP is unique in i. being grounded in
a testable, evidence based psychological model of sui-
cidal thoughts and acts, and ii. having an explicit and
central focus on suicidal thoughts and behaviours.
Three pilot Randomised Controlled Trials (RCTs) have
shown that the CBSP intervention is feasible and accept-
able when adapted for use across a range of settings, and
have suggested that it can be efficacious in reducing sui-
cidal thoughts and acts. The first found reductions in
measures of suicidal ideation and suicidal probability in
people experiencing non-affective psychosis who lived in
the community [30, 43]. The second, found that suicidal
behaviours were less frequent in male prisoners follow-
ing the CBSP intervention [31]. The third, found that
this intervention was feasible, acceptable, and safe, and
suggested that it may be cost-effective when used in psy-
chiatric in-patient settings [44]. This means that the evi-
dence from pilot RCTs across three diverse settings
indicated that the CBSP suicide focussed therapy has the
potential to counter suicidal experiences.
In order to develop this work further it is important to
test the efficacy of CBSP in a larger, definitive, RCT in
people with severe mental health problems who are vul-
nerable to suicidal experiences. It is also important to
test the extent to which the underlying psychological
mechanisms, on which CBSP is based are supported
when applied to people with non-affective psychosis.
Therefore, we propose to test CBSP adapted for people
with non-affective psychosis (CBSPp) in an RCT, with
two arms i. the CBSPp intervention plus treatment as
usual (CBSPp plus TAU) and ii. treatment as usual
(TAU) across three time points of baseline, 6 months
follow-up (at therapy cessation), and 12 months follow-
up. Our CARMS RCT is novel because i. it is founded
on a testable psychological theory, ii. it is based on pilot
work in diverse settings of a suicide focused cognitive
therapy, and iii. unlike many of the studies included in
recent meta-analytic reviews [17–21], it attempts to
understand the mechanisms and the efficaciousness of a
psychological ‘talking’ therapy in a population of individ-
uals with severe mental health problems who are highly
vulnerable to suicidal thoughts and acts. A more com-
plex trial design is inappropriate given that the CARMS
RCT advances pilot work.
The primary outcome is suicidal thoughts and acts at
6 months following entry to the trial. It is predicted that
i. suicidal thoughts and acts will be less frequent and less
severe in the intervention condition compared to the
control condition, measured at therapy cessation (6
months) and after a 12 month follow up (FU) period
compared to baseline; ii. negative appraisals of social
support, emotional regulation, and interpersonal prob-
lem solving will lead to stronger perceptions of being
defeated, trapped and hopeless, which will in turn lead
to suicidal thoughts and behaviours over time; and iii.
the treatment condition will result in less severe negative
appraisals, and reduced perceptions of defeat, entrap-
ment and hopelessness compared to the control condi-
tion. A more exploratory prediction is that symptoms of
psychosis, particularly positive symptoms of hallucina-
tions and delusions and their associated distress, will
strengthen the relationships between negative appraisals,
perceptions of defeat, entrapment and hopelessness and
suicidal thoughts and behaviours. The acceptability and
cost-effectiveness of the intervention will also be exam-
ined. Regarding the CBSPp therapy, we will attempt to
gain information about the therapy process, the thera-
peutic alliance, engagement and adherence.
Methods/Design
Patient and public involvement (PPI)
A central, and fundamentally important component of
the CARMS RCT is that people who are Experts-By-
Experience (EBEs) have been involved in the design and
set up of this project. Indeed, some of the co-
investigators on the CARMS trial have personal experi-
ence of suicidality. We have established a CARMS
specific PPI group with suicidal experiences and severe
mental health problems who will be invited to have dir-
ect involvement in all the research stages, decision mak-
ing processes, and suicidality training processes, of the
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CARMS project throughout its duration. It is becoming
increasingly recognized that this type of PPI involvement
is essential in any research projects investigating mental
and physical health issues including those with economic
implications [45–48].
Study design: the RCT
The CARMS trial involves both an RCT and a nested
qualitative component within the design. The trial was
registered with ClinicalTrials.gov (reference NCT0311491
7) where it was first posted 14th April 2017. It was also
registered with ISRCTN (reference ISRCTN17776666
https://doi.org/10.1186/ISRCTN17776666) with registra-
tion being assigned 5th June 2017). Registration was ac-
cepted before recruitment commenced. The design of the
trial follows Consolidated Standards of Reporting Trials
(CONSORT; http://www.equator-network.org/reporting-
guidelines/consort/) and SPIRIT guidelines (Standard
Protocol Items: Recommendations for Intervention Trials;
http://www.spirit-statement.org/), and the TIDieR check-
list and guide; Template for Intervention Description and
Replication (BMJ 2014; 348:g1687).
The design is a single-blind RCT with two parallel
arms. Outcome variables assessing suicidal experiences
will be collected at baseline, and at 6 and 12months
follow-up time points. Data pertaining to clinical and
mediational variables will be collected at baseline, after
therapy cessation (6 months), and at the 12month
follow-up time point. Health economics measures
(assessed over the previous 6months) will be collected
at baseline and at the 12 month follow-up time-point
to allow comparison over the pre-trial and post
randomization period. It is anticipated that up to 24
individual therapy sessions, of up to an hour, will be
offered over 6 months. Participants will be independ-
ently randomised to one of the two trial arms, with
stratification based on whether the participant is or is
not prescribed anti-depressant medication (as this
could affect the primary outcome variable) and the
NHS sites over which the trial is being tested (see
Fig. 1).
Study design: the qualitative component
There are four qualitative work-streams. The aim of the
first is to investigate perceptions of both participants
and health professionals, including mental health profes-
sionals, concerning aspects of the implementation of a
psychological talking therapy focused on ameliorating
suicidal thoughts and behaviours in people experiencing
non-affective psychosis. The second work-stream ex-
plores psychological mechanisms which are perceived to
be precursors and drivers to suicidal thoughts and acts.
The third, examines acceptability of the experience of
the therapy from the perspective of those randomised to
CBSPp. The fourth work-stream investigates the experi-
ences of participants taking part in research which has a
suicide focus.
A purposive sampling matrix will be used to maximise
diversity in the participants recruited to the qualitative
work streams. Semi-structured, one-to-one, interviews
will be used across all the qualitative work streams to
generate the data.
Recruitment to the RCT (the host site is Greater
Manchester Mental Health NHS Foundation Trust)
Potential participants will be identified by mental health
professionals in the participant’s mental health care team
(including community mental health teams, early inter-
vention services, and inpatient psychiatric wards) using
the inclusion and exclusion criteria listed below. These
professionals will then ascertain whether participants are
willing to receive information about the study and to be
contacted by a CARMS researcher. If so, potential par-
ticipants will be contacted in order to provide them with
a Participant Information Sheet (PIS) and to check eligi-
bility for the trial. At least 24 h after receiving the PIS,
participants will be asked to confirm whether they want
to take part in the CARMS project and, if so, to provide
informed consent.
Posters and flyers will be distributed in areas accessible
to potential participants e.g., health service waiting
rooms, inpatient wards, relevant community venues,
where feasible. In addition, information about the
CARMS trial will be disseminated via mental health
charities. Recruitment materials will be used to enable
participants to request that a member of their mental
health care team (e.g., care co-ordinator) refer them into
the CARMS trial. A dedicated CARMS website will also
be used to provide information about the CARMS trial
(https://sites.manchester.ac.uk/carms/). In addition, re-
cruitment materials (e.g., posters, flyers, newsletters) will
be distributed to mental health service providers. Mem-
bers of the CARMS team, including researchers and
therapists, will deliver mental health team briefings
about CARMS as appropriate.
Study design: eligibility criteria
The eligibility criteria are i. ICD-10 diagnosis relating to
non-affective psychosis (ICD 10, i.e., F20 – F29), ii. self-
reported experiences of suicidal thoughts, urges, plans
and/or acts in the past 3 months, iii. in contact with
mental health services and under the care of a mental
health services clinical team (e.g., NHS community or
inpatient mental health care teams, early intervention
teams, crisis teams, home treatment teams), iv. aged 18
or over, v. sufficient English to complete questionnaires
(hence, not needing an interpreter), vi. able to give in-
formed consent as assessed by either a responsible
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clinician or by CARMS research staff following the
British Psychological Society’s guidelines on gaining
informed consent (http://www.bps.org.uk/sites/default/
files/documents/code_of_human_research_ethics.pdf).
The exclusion criteria are i. dementia, or an organic
brain disorder, ii. unable to complete assessments due to
language barriers, and iii. currently taking part in a clin-
ical trial. A short screening procedure will be used to as-
sess eligibility.
Study design: withdrawal criteria
The withdrawal criteria are i. the participant decides to
withdraw from the trial for any or no reason, and ii. the
participant is lost to follow-up. However, data will be in-
cluded in the analyses up to the point of withdrawal with
appropriate consent.
Study design: randomisation and blinding
Randomisation will take place only when participants
have consented to participate and after the baseline as-
sessments have been completed. Hence, participants will
consent to take part without knowing their group alloca-
tion. The Manchester Academic Health Sciences Centre
(MAHSC), Clinical Trials Unit (CTU) will oversee the
blocked stratified randomisation procedures. Researchers
conducting the assessments, the trial statistician, one of
the CARMS Trial Co-Principal Investigators, and mem-
bers of the CTU conducting data handling and data
monitoring will be blind to the randomised allocation
group of participants. Procedures will be in place if a
CARMS researcher becomes unblinded. In such an in-
stance of unblinding then a different researcher will be
allocated to work with that participant. We will not
disclose the reason for this allocation. Indeed, we will
strategically re-allocate researcher resource so that re-
allocation is a frequent occurrence for researchers, espe-
cially given the wide geographical distribution of sites.
Study design: sample size and power calculations
Based on power analyses, the target sample size is 125
participants in each arm (treatment and control), mean-
ing that there will be a target of 250 participants in total
for the primary analyses at 6 months across the partici-
pating sites. To account for attrition of 25%, it is antici-
pated that up to 333 participants will be recruited into
the baseline phase of the trial. It is estimated that 50% of
people approached will decline to take part. Therefore,
approximately 666 participants will be identified as eli-
gible and screened.
Fig. 1 The CARMS Trial design
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We will use an approach based on a simple t-test for
the between group comparison in the primary suicide
outcome measure which is specifically designed to ac-
count for differential clustering or partial nesting be-
tween the two arms [49]. It is implemented using the
command clsampsi- in Stata [50]. This approach re-
quires the following assumptions:
a. Effect size: A clinically meaningful difference on the
primary suicide outcome variable (ASIQ) from
baseline to the 6 month follow-up time-point is esti-
mated as a 16 point reduction, which corresponds
to an effect size of 0.42, based on pilot data [30].
b. Attrition: We are allowing for an attrition rate of
25% from baseline to final follow-up.
c. Clustering: we account for clustering of outcomes
within the participants sharing a therapist in the
treatment arm with an ICC = 0.02.
d. Random allocation: 1:1 random allocation, 0.05
significance level, and 80% statistical power.
For our proposed mediational analyses to test psycho-
logical mechanisms, a sample size of approximately 250
has greater than 80% power to detect a proportion medi-
ated of 35%, and over 70% power to detect a proportion
mediated of 30% (calculated using PowerMediation in R).
In sum, our sample size will have sufficient power for
our proposed efficacy and mediation analyses.
Study design: study arms of treatment and control
groups
Treatment arm: the CBSPp intervention plus TAU
anticipated as 24 weekly 50 min sessions
The CBSPp intervention is a one-to-one, formulation
based approach. Initial sessions focus on engaging the
individual in exploring their suicidal thinking and behav-
iours and how they relate to key underlying psycho-
logical constructs and to their key emotions, cognitions
and behaviours. Ways in which these types of thoughts
and behaviours interact with their experiences of psych-
osis, life circumstances and history is also explored to
reach a shared formulation and understanding of their
suicidal thoughts, plans, and acts. The approach, collab-
oratively, generates possible actions which are likely to
modify negative appraisals of emotional regulation, im-
prove perceptions of social support, and perceptions of
interpersonal problem solving, and to influence other
main drivers of their suicidal thoughts and acts, for ex-
ample, distressing symptoms of psychosis. As a conse-
quence, it is hypothesised that perceptions of defeat,
entrapment, and hopelessness will be improved indir-
ectly, although, perceptions of defeat, entrapment and
hopelessness will also be worked on directly during the
therapy [14, 30, 31]. Therapists will be trained in CBT
techniques and further trained in CBSPp.
Control arm: TAU only
TAU will include usual clinical care. This is likely to be,
although not exclusively, in the form of assessment and
intervention from a multi-disciplinary mental health
team as an outpatient or inpatient, prescription of psy-
chiatric medication, regular monitoring, and social sup-
port. Where possible, we will document the types of
TAU offered to and/or received by participants.
Proposed outcome measures: primary, secondary,
mechanistic, clinical, therapy process, and health economics
variables
Primary suicide outcome measure This is the Adult
Suicidal Ideation Questionnaire [ASIQ] [51] which is a
self-report measure comprising 25 items. Suicide idea-
tion is a predictor of suicide attempts and suicide death
[52]. Participants are asked to report the frequency of
thoughts about death and suicide in the last month
using a 7 point Likert scale. For individuals attending
psychiatric outpatient clinics with a history of suicide at-
tempts, internal consistency was reported as .97. Test-
retest reliability was also reported to be high (r = .95) in
a mixed sample including those with a history of suicide
attempts [51]. The primary analyses examine changes in
the ASIQ from baseline to the 6 month time-point.
Secondary suicide outcome measures We will use the
following measures, the first two of which are self-report
measures.
1. The Suicide Probability Scale [53] comprises 36 items
and measures four components of suicidal experiences
including suicidal ideation, hopelessness, negative self-
evaluations and hostility. The internal reliability for this
measure was found to be high in a sample including
psychiatric inpatients with a Cronbach’s alpha score re-
ported as .93 [53].
2. The Beck Scale for Suicidal ideation [54] measures
recent suicidal ideation, plans, and intent over the
past week (19 items) together with previous attempt
history (2 items). This self-report measure has been
reported as having an alpha coefficient of 0.96 and
test–retest reliability of r = 0.88 with people who
were psychiatric inpatients and with those with ex-
periences of non-affective psychosis [55].
3. Self-reported frequency of suicidal thoughts, plans
and attempts over the past 6 months. Where
feasible, we will collect data from clinical case notes
and documentation of adverse events, including
those considered to be serious.
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Mechanistic outcome variables Each mechanistic vari-
able assesses key components of the predicted psycho-
logical pathways to suicidal experiences [22] using self-
report questionnaires:
1. The Difficulties in Emotional Regulation Scale [56]
measures self-reported appraisals of emotional con-
trol. Four aspects of emotional regulation comprise
the scale which are i. an awareness and reflective
capacity, or understanding, with respect to emo-
tions, ii. the ability to accept thoughts and behav-
iours reflective of emotions, iii. feeling in control of
emotional reactions, and iv. feeling able to use ef-
fective emotional regulation strategies. Typically,
total scores on this scale have been found to correl-
ate positively with a range of measures of psycho-
logical mental health problems in a large sample
presenting at an outpatient psychiatric clinic. In
addition, internal reliability was reported as 0.97 in
this sample [57].
2. The Social Problem-Solving Inventory Short Form
[58] tests appraisals of social problem solving and
has five sub-scales (positive problem orientation,
negative problem orientation, rational, impulsive,
and avoidant problem solving styles). Overall, there
are 25 items. Alpha reliabilities have been reported
as ranging between 0.85 and 0.96 in adolescents,
young adults, middle aged and elderly adults [58].
3. The Social Support Appraisals Scale [59] assesses
perceptions of available social support using 23
items. Data generated from five heterogeneous
student/college samples and five community
samples indicated Cronbach’s alpha reliability
calculations to be between 0.80 and 0.90 [59].
4. The Beck Hopelessness Scale [60] measures
perceptions of having a negative future with 20,
binary choice, yes/no responses. Hopelessness has
been shown to be a robust predictor of suicidal
experiences even compared with measures of
depressed mood states [61]. Reliability estimates
have been recorded as exceeding 0.88 in a range of
samples including those with suicidal thoughts and
behaviours and severe mental health problems [60,
62, 63].
5. The Defeat and Entrapment scales [64] assess
perceptions of being defeated and trapped both of
which use 16 items. Perceptions of both defeat and
entrapment have been robustly implicated in
pathways to suicidal experiences in people
experiencing depression, anxiety [32], and also in
those with non-affective psychosis [28]. In people
with non-affective psychosis who also experienced
some level of suicidal thoughts and behaviours, in
the past or currently, the Cronbach’s alpha
coefficients were reported to be 0.86 for defeat and
0.95 for entrapment [28].
Clinical variables Mental health problems pertaining to
psychosis, depression, and functioning, are measured in
clinical interviews as follows: Positive and Negative Syn-
drome Scale [PANSS] [65], the Psychotic Symptom Rat-
ing Scales [PSYRATS] [66], the Personal and Social
Performance Scale [PSP] [67] and the Calgary Depression
Scale [CDS] [68]. The PANSS is the most widely used
measure of positive, negative and general symptoms ex-
perienced by people with psychosis and was shown to
have sound psychometric properties using a response
analysis [69]. The PSYRATS shows excellent reliability
across raters and has robust validity [66]. The PSP has
excellent face validity and reliability with the majority of
ratings taking place in those with schizophrenia [67].
The CDS was specifically designed for people with
schizophrenia and was reported as having excellent reli-
ability estimates [68].
Information about current medication for mental
health problems (e.g., anti-psychotic and anti-depressant
medication) will be recorded from self-reports and sup-
plemented from clinical records where possible.
Health economics measures Participant-level costs will
be generated for each participant in both the CBSPp
treatment and TAU control arms. Costs will comprise
the costs of the intervention, of TAU, and downstream
costs. Costs will be constructed from a combination of
trial-based resource use (NHS contacts and the Client
Service Use Receipt Inventory [CSRI] amended for our
trial, to monitor service use) with published unit costs,
allowing comparison of CBSPp with TAU in terms of
costs to the NHS and PSS. Several methods are available
to collect resource-use. The most popular have been
resource-use questionnaires, resource-use diaries, and
electronic record searches [70–72]. The Clients Service
Receipt Inventory (CSRI) [73] is a commonly used
method for the retrospective collection of resource-use
information which has been implemented in the eco-
nomic evaluation of a variety of physical and mental
health care interventions [74–77]. The CSRI covers a
range of economic factors including participant’s use of
health and social care services, accommodation and
living situation, income, employment and benefits (the
CSRI is available from the Database of Instruments for
Resource-use Measurement [DIRUM] website: http://
www.dirum.org/assets/downloads/634462388066137028-
CSRI.pdf). Similarly to other studies, we are using a
modified version of the CSRI, based on the format and
questions of the CSRI but ‘modified’ to reflect the care
pathways of our study participants. Examples include the
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use of mental health care services (community teams,
crisis teams, inpatient psychiatric admission),
The EQ–5D-3 L can reflect different levels of psychosis
symptomatology, be responsive to intervention effects
[78–80], and correlates with the PANSS and Brief Psychi-
atric Rating Scale - Expanded (BPRS-E) [81]. However, the
EQ-5D-3 L showed significant ceiling effects compared
with PANSS and BPRS-E. The EQ-5D-5 L [82] is less
prone to ceiling effects in a range of health problems [83–
86] and the increased sensitivity of EQ-5D-5 L may also
favour Quality-Adjusted Life-Years (QALY) gains even if
the changes in utility are smaller [87]. Hence we will use
will use the EQ-5D-5 L. QALYs will be calculated by
attaching available utility weights to the health states gen-
erated from the EQ-5D-5 L, using area under the curve
methods with an assumption of a linear change between
time points, controlling for baseline.
Demographic information We will collect demo-
graphic information at baseline and then check at
follow-up whether factors such as relationship status,
work status and education have changed at the two
follow-up periods of 6 and 12months. We will collect
data concerning age, ethnicity, gender, type of work,
length of time doing this work, and highest level of
education.
Assessment of mood A visual analogue scale (0–100)
will be used to assess mood prior to all assessment ses-
sions, and after those sessions where possible. This is to
get a very quick rating of whether the sessions have
negatively impacted mood and will be used to feed into
assessments of suicide risk.
Therapy process measures of therapeutic alliance,
engagement and adherence For those in the therapy
arm of the trial, the therapeutic alliance will be assessed
twice, after approximately four sessions and towards the
end of the therapy, with the Working Alliance Inventory
– short form [88] completed by the therapist and the
participant. Therapists will also record the following in-
formation for each participant in the therapy arm of the
trial as appropriate and where possible: i. number of ses-
sions attended and ii. duration of each session.
Data analyses of the CARMS RCT
Analysis of the trial data to assess efficacy
A statistical analysis plan will be prepared before any
analysis is undertaken, and agreed with the independent
DMEC and TSC. Reporting will follow the CONSORT
for Psychological and Social Interventions. All analyses
and summary statistics will be conducted on the
Intention-To-Treat (ITT) population which is defined as
all participants randomised regardless of completion of
therapy or withdrawal from the study. All analyses will
be carried out at the end of the last follow-up assess-
ments, and no interim analysis is planned.
Consideration will be given to potential biases arising
from loss to follow-up.
Analyses will be conducted in Stata version 16 or later.
Descriptive statistics within each randomised group will
be presented for baseline values. These will include
counts and percentages for binary and categorical vari-
ables, and means and standard deviations, or medians
with lower and upper quartiles, for continuous variables,
along with minimum and maximum values and counts
of missing values. There will be no tests of statistical sig-
nificance or confidence intervals for differences between
randomised groups on any baseline variable.
Treatment effects on primary and secondary outcomes
will be estimated using linear mixed models fitted to
outcome variables at all time points. Fixed effects will be
NHS site, anti-depressant use at baseline (yes/no), base-
line assessment for the outcome under investigation,
treatment, time and time*treatment interactions. Partici-
pant will be included as a random intercept to account
for repeated measures. If the number of therapists is dif-
ferent from the number of NHS sites, we will include
therapist as an additional random effect.
Marginal treatment effects will be estimated for pri-
mary outcome (ASIQ score at 6 months), and for pri-
mary and secondary outcomes at all other time points,
and reported separately as adjusted mean differences in
scores between the groups with 95% confidence intervals
and 2-sided p-values. Cohen’s D effect sizes will be cal-
culated as the adjusted mean difference of the outcome
divided by the sample standard deviation of the outcome
at baseline. These will be displayed in a forest plot show-
ing the treatment effects on the primary and the second-
ary outcomes at 6 months.
We will allow for the presence of missing data under
the assumption that the data are Missing At Random,
conditional on the covariates in the model, and as a sen-
sitivity analysis include other baseline measures as pre-
dictors of future loss to follow-up.
To account for the possible prognostic effect of anti-
depressant medication on outcomes, we will include
anti-depressant use at baseline (yes/no) as a stratifying
factor. We acknowledge that use of anti-depressant
medication after randomisation might account for a pro-
portion of any observed treatment effect because it
might lie on the causal pathway between randomisation
and outcome but it is not targeted by the intervention
itself. If there is a significant differential effect in the
uptake of anti-depressant medication between the treat-
ment and control groups, we will assess the role of anti-
depressant medication as a mediator, in addition to our
hypothesised target mediators.
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Analysis of the trial data to assess mechanisms
We will perform this analysis using methods similar to
those of Baron and Kenny [89] but advanced by newer
approaches of structural equation models, instrumental
variable analyses, and principal stratification to allow for
hidden confounder variables [90–92]. Moderator ana-
lyses will focus on examining the effects of psychotic
symptoms as an amplifier [93]. Stata version 16 or later
will be used for all the analyses.
Analyses of the qualitative work streams
It is anticipated that data will be largely analysed using
an inductive Thematic Analysis (TA) [94, 95] approach
taking an interpretative stance. Coding will be under-
taken inductively at the manifest level. Following famil-
iarisation, a coding framework will be developed and
codes assigned to themes. Data generation and analysis
will occur in parallel using a constant comparative ap-
proach [96]. Disconfirming evidence will be sought and
the analysis refined accordingly where possible. Data
generation will cease when theoretical saturation appears
to have been achieved. Regular discussion of emerging
codes and themes will take place with the wider research
team which includes service users, clinical and academic
psychologists, and psychiatrists. This is a recognised
method for maximising the trustworthiness of the final
analysis [97].
Economic evaluation
Patient-level costs will be generated for each participant
in the treatment (CBSPp intervention plus TAU) and
TAU alone arms of the trial. Costs will comprise those
of the treatment arm, those of TAU arm, and down-
stream costs. Costs will be constructed from a combin-
ation of trial-based resource use (NHS contacts and the
Client Service Use Receipt Inventory [CSRI] amended
for our proposed trial, to monitor service use) with pub-
lished unit costs, allowing comparison of treatment with
TAU in terms of costs to the NHS and PSS. The CSRI
[98] is a commonly used method for the retrospective
collection of resource-use information which has been
implemented in the economic evaluation of a variety of
physical and mental health care interventions [75, 76,
99, 100]. The CSRI covers a range of economic factors
including a participant’s use of health and social care
services, accommodation and living situation, income,
employment and benefits (CSRI is available from the
Database of Instruments for Resource-use Measurement
(DIRUM) website: (http://www.dirum.org/assets/down-
loads/634462388066137028-CSRI.pdf). Similarly to other
studies, we are using a modified version of the CSRI,
based on the format and questions of the CSRI but
‘modified’ to reflect the care pathway of our study
participants.
Participant-level costs will be generated for each par-
ticipant in the Treatment and TAU arms from a com-
bination of trial-based resource use with published unit
costs. The unit costs of resource use will be taken from
publicly available sources including current editions of
NHS reference costs and the Unit Costs of Health &
Social Care [101, 102]. Costs will be compared between
the two groups using a bootstrapped regression model
(as the data are likely to be skewed).
Custodians of the data
It should be noted that the Co-Principal Investigators
are the custodians of the data.
Discussion
The risk of suicide fatalities in people who experience
severe mental health problems, including those with
non-affective psychosis, is extensively elevated compared
to suicide fatalities in the general population [8, 10, 103].
In addition, the distress of experiencing suicidal
thoughts and acts can be severe, perhaps, especially
when linked with mental health problems, such as, hal-
lucinations and delusions [9, 104–106]. Within the exist-
ing literature, there has been a tendency to focus on the
extent to which therapies, including psychological talk-
ing therapies, result in the reduction of symptoms
indicative of mental health problems rather than on
redressing suicidal experiences [14, 30, 31, 107]. Evi-
dence indicates that suicidal experiences need to be tar-
geted by psychological talking therapies directly [18, 30,
31, 108]. However, the development of talking therapies
for suicidal experiences is in its infancy [14, 30, 31, 107,
109]. The CARMS project, i.e., a multifaceted RCT, is
important because it redresses this gap.
Six strengths of the CARMS RCT should be empha-
sised, and discussed.
First, the therapy being evaluated in the CARMS RCT
is based on a theoretical psychological model, namely
the SAMS, of the psychological pathways thought to
underlie suicidal experiences [22]. The SAMS resonates
with other recent psychological approaches to under-
standing suicidal thoughts and acts [23–26]. Both the
SAMS, and contemporary psychological models of sui-
cidal experiences, have gained support from qualitative,
quantitative and epidemiological methods [22, 28, 32–
34, 63, 110–119].
Second, the CARMS CBSPp intervention has been de-
veloped from evidence based on working with people
with a range of severe mental health problems, such as
those given diagnoses of schizophrenia, PTSD, the bipo-
lar disorders and depression [32, 62, 63, 107, 111–115,
120]. This means that the intervention has a mechanis-
tic, scientific basis which examines both transdiagnostic
and the specificities of mental health problems, for
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example hallucinations and delusions, in the pathways to
suicidal thoughts and behaviours [9]. In accord with this
principle, the CARMS trial aims to examine the extent
to which specific experiences of psychosis, such as, the
distress caused by hallucinations and delusions are
primary triggers for suicidal experiences and/or amplify
other known psychological precipitants of suicidal
thoughts and experiences, such as, a sense of hopeless-
ness, defeat and entrapment.
The third strength is that the psychological talking
therapy, i.e., CBSPp, used in the CARMS trial is sui-
cide focussed, personalised, and formulation driven.
This psychological talking therapy is supported by
evidence pertaining to acceptability, feasibility and
efficaciousness from qualitative and quantitatively de-
signed pilot work with people living in the commu-
nity with psychosis, prisoners, and psychiatric in-
patients [30, 31, 43, 107–109, 121–123]. These indi-
viduals are exceptionally vulnerable to suicidal
thoughts, acts and deaths because of their complex,
and often severe, mental health problems.
Fourth, CARMS aims to assess not only the
efficaciousness of our suicide-focussed psychological
intervention, but to advance our understanding of the
psychological mechanisms underlying suicidal thoughts
and behaviours. It is vitally important to advance these
mechanisms in a context of understanding how to ad-
dress the cyclical, and often, unpredictable patterns in
which people transition from, and between suicidal
thoughts, urges, plans and acts [118, 119].
Fifth, there are four qualitative work streams nested
within the CARMS trial. These work streams will probe
psychological mechanisms; barriers and facilitators to
providing the CARMS trial intervention in the ‘real-
world’; implementation challenges and solutions; aspects
of the therapy which were perceived as being both posi-
tive and negative; and the experiences of taking part in
suicide research. It has been shown that qualitative work
can often contextualise aspects of the design of trials
which can remain hidden wherein aspects of interven-
tions may, otherwise, be somewhat tacit [43, 121–126].
Sixth, Patient and Public Involvement (PPI) has been
used extensively in the lead-up to this CARMS trial be-
ing funded. Furthermore, people who are Experts By Ex-
perience with respect to suicidality and severe mental
health problems are integral to all stages of the trial
which is vital to RCT designs [45].
Four limitations of the CARMS RCT are also
worthy of discussion. First, in a meta-analysis of 18
trials of cognitive based therapy for self-harm, the ex-
tent to which the therapy was perceived as effective
depended on the quality of reporting the effects of
the Treatment As Usual (TAU) arm of the trial with
a bias in favour of trials which did not provide
enough specifics of the TAU arm [127]. In the
CARMS RCT an attempt will be made to collect as
much information as possible regarding treatment as
usual. However, it must be acknowledged that being
able to collect this type of information will be chal-
lenging for a number of reasons, including, that
people may access therapies from a range of sources
which may be not be well documented or effectively
reported.
Second, the design is single-blinded meaning that nei-
ther the therapists nor the participants can be blind to
treatment. This is, of course, a necessary limitation. The
CARMS researchers carrying out the assessments, those
performing data entry in the Clinical Trials Unit, the
trial statistician and one Principal Co-Investigator will
be blinded to treatment allocation with any unblindings
noted. This lends trustworthiness to the data collected
and analysed which serves to counter this limitation to
an extent.
Third, the participants have experiences of non-
affective psychosis and recent suicidal thoughts and be-
haviours. That they have recent suicidal experiences is a
strength of the CARMS trial. However, a limitation is
that it is unclear the extent to which the CARMS ther-
apy, i.e., CBSPp, would need to be adapted for people
experiencing other mental health problems together with
suicidal experiences. So, it is uncertain whether the ther-
apy used in the CARMS trial is, or can be, generically in-
troduced across mental health services. That said, pilot
work with male prisoners and inpatients on psychiatric
wards included people with a range of mental health prob-
lems, which provides some reassurance that the CARMS
CBSPp intervention can be applied to people with a di-
verse range of mental health problems [107, 108].
Fourth, the CARMS trial assesses mechanisms and
efficaciousness. It will also examine perceptions of key
stakeholders (e.g., service users, mental health service
providers and mental health service commissioners)
about potential implementation barriers and facilitators
within the qualitative work. However, it is limited in
assessing whether any benefits of CBSPp can be imple-
mented in mental health services to effect clinical benefi-
cial change in ‘real-life’ settings, that is, outside of an
RCT. That said, participants will be recruited from rou-
tine mental health services and the therapists will be in-
dividuals seconded from, and/or with experience of,
mental health services which off-sets this limitation.
In conclusion, the CARMS RCT addresses a crucially
important mental health need which is to determine how
to diminish suicidal thoughts, urges, plans and acts in
people with severe mental health problems, with a focus
on those with non-affective psychosis, who are at elevated
risk from death by suicide and who experience severe dis-
tress which leads them to have suicidal thoughts, to make
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plans to die by suicide and to make suicide attempts. The
CARMS psychological intervention, CBSPp, and the RCT
is theoretically grounded and supported by a range of em-
pirical evidence based on numerous research designs in
diverse populations.
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